IBDEI1DY ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22412,1,3,0)
 ;;=3^Rising PSA After Tx for Prostate CA
 ;;^UTILITY(U,$J,358.3,22412,1,4,0)
 ;;=4^R97.21
 ;;^UTILITY(U,$J,358.3,22412,2)
 ;;=^5139228
 ;;^UTILITY(U,$J,358.3,22413,0)
 ;;=R82.81^^73^961^85
 ;;^UTILITY(U,$J,358.3,22413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22413,1,3,0)
 ;;=3^Pyuria
 ;;^UTILITY(U,$J,358.3,22413,1,4,0)
 ;;=4^R82.81
 ;;^UTILITY(U,$J,358.3,22413,2)
 ;;=^101879
 ;;^UTILITY(U,$J,358.3,22414,0)
 ;;=I25.118^^73^961^8
 ;;^UTILITY(U,$J,358.3,22414,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22414,1,3,0)
 ;;=3^Athscl Hrt Dis of Native Cor Art w/ Oth Angina
 ;;^UTILITY(U,$J,358.3,22414,1,4,0)
 ;;=4^I25.118
 ;;^UTILITY(U,$J,358.3,22414,2)
 ;;=^5007110
 ;;^UTILITY(U,$J,358.3,22415,0)
 ;;=J44.0^^73^961^17
 ;;^UTILITY(U,$J,358.3,22415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22415,1,3,0)
 ;;=3^COPD w/ Lower Respiratory Infection
 ;;^UTILITY(U,$J,358.3,22415,1,4,0)
 ;;=4^J44.0
 ;;^UTILITY(U,$J,358.3,22415,2)
 ;;=^5008239
 ;;^UTILITY(U,$J,358.3,22416,0)
 ;;=J44.1^^73^961^16
 ;;^UTILITY(U,$J,358.3,22416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22416,1,3,0)
 ;;=3^COPD w/ Acute Exacerbation
 ;;^UTILITY(U,$J,358.3,22416,1,4,0)
 ;;=4^J44.1
 ;;^UTILITY(U,$J,358.3,22416,2)
 ;;=^5008240
 ;;^UTILITY(U,$J,358.3,22417,0)
 ;;=I50.22^^73^961^15
 ;;^UTILITY(U,$J,358.3,22417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22417,1,3,0)
 ;;=3^CHF-Systolic (HFrEF),Chronic
 ;;^UTILITY(U,$J,358.3,22417,1,4,0)
 ;;=4^I50.22
 ;;^UTILITY(U,$J,358.3,22417,2)
 ;;=^5007241
 ;;^UTILITY(U,$J,358.3,22418,0)
 ;;=I50.32^^73^961^13
 ;;^UTILITY(U,$J,358.3,22418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22418,1,3,0)
 ;;=3^CHF-Diastolic (HFpEF),Chronic
 ;;^UTILITY(U,$J,358.3,22418,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,22418,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,22419,0)
 ;;=I50.42^^73^961^12
 ;;^UTILITY(U,$J,358.3,22419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22419,1,3,0)
 ;;=3^CHF-Combined Systolic & Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,22419,1,4,0)
 ;;=4^I50.42
 ;;^UTILITY(U,$J,358.3,22419,2)
 ;;=^5007249
 ;;^UTILITY(U,$J,358.3,22420,0)
 ;;=I50.84^^73^961^14
 ;;^UTILITY(U,$J,358.3,22420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22420,1,3,0)
 ;;=3^CHF-End Stage
 ;;^UTILITY(U,$J,358.3,22420,1,4,0)
 ;;=4^I50.84
 ;;^UTILITY(U,$J,358.3,22420,2)
 ;;=^5151391
 ;;^UTILITY(U,$J,358.3,22421,0)
 ;;=E11.22^^73^961^27
 ;;^UTILITY(U,$J,358.3,22421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22421,1,3,0)
 ;;=3^DM Type 2 w/ Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,22421,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,22421,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,22422,0)
 ;;=E11.21^^73^961^28
 ;;^UTILITY(U,$J,358.3,22422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22422,1,3,0)
 ;;=3^DM Type 2 w/ Nephropathy,Unspec
 ;;^UTILITY(U,$J,358.3,22422,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,22422,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,22423,0)
 ;;=E11.42^^73^961^32
 ;;^UTILITY(U,$J,358.3,22423,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22423,1,3,0)
 ;;=3^DM Type 2 w/ Peripheral Neuropathy
 ;;^UTILITY(U,$J,358.3,22423,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,22423,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,22424,0)
 ;;=E11.43^^73^961^26
 ;;^UTILITY(U,$J,358.3,22424,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22424,1,3,0)
 ;;=3^DM Type 2 w/ Autonomic Neuropathy
